ADVERTISEMENT

ADVERTISEMENT

Rare, neuro drugs near a breakthrough moment

New tools and diagnostic capabilities were discussed at the USA–India Chamber of Commerce’s BioPharma & Healthcare Summit in Boston

Panel discussion at USA–India Chamber of Commerce’s BioPharma & Healthcare Summit in Boston / New India Abroad

Breakthroughs in neuroscience, rare diseases and precision medicine are bringing the biopharma industry closer to long-awaited advances, but challenges in regulation, patient selection and clinical trials continue to slow progress, industry leaders said at a high-level panel.

At the USA–India Chamber of Commerce’s BioPharma & Healthcare Summit in Boston, executives said new tools, better targets and emerging modalities are reshaping how companies approach complex neurological and rare diseases.

This post is for paying subscribers only

SUBSCRIBE NOW

Comments

Related

To continue...

Already have an account? Log in

Create your free account or log in